Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo(Icahn School of Medicine at Mount Sinai), David R. Gandara(University of California, Davis), Philip C. Mack(UC Davis Comprehensive Cancer Center), Luis E. Raez(Florida International University), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Nir Peled(Shaare Zedek Medical Center), Heather A. Wakelee(Palo Alto Institute), Martin Reck(German Center for Lung Research), David P. Carbone(Vanderbilt University), Murry W. Wynes(International Association for the Study of Lung Cancer), Tony Mok(Chinese University of Hong Kong), Fred R. Hirsch(Tisch Hospital), Lecia V. Sequist(Harvard University), Frances A. Shepherd(University Health Network), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Jonathan W. Riess(Comprehensive Blood & Cancer Center), Fabrice Barlési(Hôpital Nord), Lynette M. Sholl(Brigham and Women's Hospital), Robert Pirker(Medical University of Vienna), Trever G. Bivona(University of California, San Francisco), Daniel Shao-Weng Tan(Memorial Sloan Kettering Cancer Center), Roy S. Herbst(Smilow Cancer Hospital)
Cited by 661
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k